Literature DB >> 29650333

EASL Recommendations on Treatment of Hepatitis C 2018.

.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29650333     DOI： 10.1016/j.jhep.2018.03.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  361 in total

1.  Strain elastography for noninvasive assessment of liver fibrosis: A prospective study with histological comparison.

Authors:  Cheng Fang; Sanjiv Virdee; Joseph Jacob; Olivia Rufai; Kosh Agarwal; Alberto Quaglia; Daniel J Quinlan; Paul S Sidhu
Journal:  Ultrasound       Date:  2019-07-23

2.  Overcoming barriers to hepatitis C elimination.

Authors:  Manuel Mendizabal; Cristina Alonso; Marcelo O Silva
Journal:  Frontline Gastroenterol       Date:  2019-02-01

3.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

4.  Hepatitis C virus infection and the kidney.

Authors:  Meghan E Sise
Journal:  Nephrol Dial Transplant       Date:  2018-07-27       Impact factor: 5.992

5.  Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.

Authors:  Swikriti Dasgupta; Michio Imamura; Evan Gorstein; Takashi Nakahara; Masataka Tsuge; Alexander Churkin; David Yardeni; Ohad Etzion; Susan L Uprichard; Danny Barash; Scott J Cotler; Harel Dahari; Kazuaki Chayama
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

6.  The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.

Authors:  Yuan-Hung Kuo; Jing-Houng Wang; Kuo-Chin Chang; Chao-Hung Hung; Sheng-Nan Lu; Tsung-Hui Hu; Yi-Hao Yen; Kwong-Ming Kee; Chien-Hung Chen
Journal:  Invest New Drugs       Date:  2019-11-08       Impact factor: 3.850

7.  Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Authors:  Kazuki Ohya; Michio Imamura; Mitsutaka Osawa; Yuji Teraoka; Kei Morio; Hatsue Fujino; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Akira Hiramatsu; Masataka Tsuge; Hiroshi Aikata; Clair Nelson Hayes; Kazuaki Chayama
Journal:  Clin J Gastroenterol       Date:  2019-08-28

8.  Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

9.  Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2020-02-07

10.  Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.

Authors:  Bülent Değertekin; Mehmet Demir; Ulus S Akarca; Haluk Tarık Kani; Enver Üçbilek; Emre Yıldırım; Fatih Güzelbulut; Ayhan Balkan; Sezgin Vatansever; Nilay Danış; Melek Demircan; Aliye Soylu; Serkan Yaras; Aysun Kartal; Ayşe Kefeli; Feyza Gündüz; Kendal Yalçın; Elife Erarslan; Murat Aladağ; Murat Harputluoğlu; Ayşegül Özakyol; Tuncer Temel; Mesut Akarsu; Hale Sümer; Mete Akın; Bülent Albayrak; İlker Sen; Hüseyin Alkım; Ahmet Uyanıkoğlu; Kader Irak; Sinem Öztaşkın; Çağrı Burak Uğurlu; Şevkican Güneş; Selim Gürel; Kenan Nuriyev; İsmail İnci; Sabite Kaçar; Dinç Dinçer; Levent Doğanay; Hüseyin Savaş Göktürk; Ali Mert; Arif Mansur Coşar; Hakan Dursun; Roni Atalay; Sabiye Akbulut; Yasemin Balkan; Hayrettin Koklu; Halis Şimşek; Osman Özdoğan; Mehmet Çoban
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.